MS
Multiple sclerosis studies underway using existing drugs
April 2, 2015Research and Development, Sales and Marketing MS, Midamor, Prozac, Rilutek, Sanofi, amiloride, covis, fluoxetine, multiple sclerosis, riluzole
Three existing drugs that fight heart disease, depression and motor neurone disease could be used to treat multiple sclerosis (MS) …
J&J and Google partner to build surgical robots
March 30, 2015Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots
The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
Google partners with Biogen on multiple sclerosis
January 30, 2015Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos
Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …
Mixed results for Biogen’s MS drug
January 9, 2015Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy
An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
FDA green lights Lemtrada for MS
November 17, 2014Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera
The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …
Teva to ditch R&D in cancer and women’s health
October 6, 2014Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, MS, R&D, Teva, cuts, generics
Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and …
FDA approves Biogen’s long-acting MS drug
August 18, 2014Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera
Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …
Roche to launch new MS collaboration
June 23, 2014Research and Development, Sales and Marketing MS, Roche, inception sciences, multiple sclerosis, versant ventures
Roche has launched a new research collaboration to investigate ways of reversing the debilitating nerve damage caused by multiple sclerosis …
Lemtrada resubmitted to FDA
June 2, 2014Sales and Marketing FDA, Lemtrada, MS, Sanofi
Sanofi has resubmitted its application for Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis (MS) to the …
Biogen Idec’s MS drug gets European approval
February 4, 2014Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera
Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …
High-dose Copaxone the right medicine for Teva
January 29, 2014Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva
The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …
Teva’s Great White Hope knocked back by Europe
January 27, 2014Sales and Marketing CHMP, EU, MS, Nerventra, Teva
The drug designed to be a follow-up to Teva’s wildly successful Copaxone has been hit by rejection in Europe, leaving …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
